Phase III Study to Determine the Efficacy of Durvalumab in Combination With Chemotherapy in Completely Resected Stage II-III Non-small Cell Lung Cancer (NSCLC)
Part of paid clinical trials in Birmingham, Alabama.
- Sponsor
- AstraZeneca
- Study ID
- NCT04385368
- Phase
- PHASE3
- Status
- Completed
Conditions
- Carcinoma, Non-Small-Cell Lung
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 130 Years
- Healthy Volunteers
- Not accepted
Interventions
- Durvalumab + SoC chemotherapy — DRUGExperimental Treatment
- Placebo + SoC chemotherapy — OTHERPlacebo Comparator
Study Details
This is a Phase III, randomized, parallel-arm, placebo controlled, double blind, multicenter study assessing the efficacy and safety of durvalumab versus placebo following SoC chemotherapy in patients with completely resected stage II-III NSCLC who are MRD+ post surgery
Key Dates
- Start date
- Jul 17, 2020
- Status verified
- Aug 2024
- Primary completion
- Aug 31, 2023
- Completion
- Aug 31, 2023
Study Design
- Enrollment
- 89 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Durvalumab + SoC chemotherapyIntravenous administration of Experimental and Standard of Care Therapy
- Placebo Comparator: Placebo + SoC chemotherapyIntravenous administration of Placebo and Standard of Care Therapy
Primary Outcome Measure
Disease-free Survival (DFS) in FAS (Using Investigator Assessments According to Response Evaluation Criteria in Solid Tumors 1.1 [RECIST 1.1]) [ Time Frame: Every 12 weeks (q12w) ± 1 week until appearance of RECIST 1.1-defined disease recurrence or until primary DFS analysis, up to 33.28 months ]
Locations (15)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Research Site | Birmingham | Alabama | 35294 | - |
| Research Site | Long Beach | California | 90806 | - |
| Research Site | Santa Rosa | California | 95403 | - |
| Research Site | West Hollywood | California | 90048 | - |
| Research Site | Miami | Florida | 33136 | - |
| Research Site | Silver Spring | Maryland | 20910 | - |
| Research Site | Minneapolis | Minnesota | 55407 | - |
| Research Site | Lincoln | Nebraska | 68510 | - |
| Research Site | Albuquerque | New Mexico | 87131 | - |
| Research Site | New York | New York | 10032 | - |
| Research Site | Durham | North Carolina | 27710 | - |
| Research Site | Spartanburg | South Carolina | 29303 | - |
| Research Site | Sioux Falls | South Dakota | 57105 | - |
| Research Site | Houston | Texas | 77090 | - |
| Research Site | Seattle | Washington | 98108-1532 | - |
Find similar trials in Birmingham, AL
Related Studies
- Molecular Analysis of Thoracic MalignanciesEnrolling By Invitation · Stanford University · Stanford, California
- KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)PHASE1/PHASE2 · Recruiting · Merck Sharp & Dohme LLC · Gilbert, Arizona
- KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)Recruiting · Merck Sharp & Dohme LLC · Gilbert, Arizona
- Development and Analysis of a Stool Bank for Cancer PatientsRecruiting · Persephone Biosciences · Fountain Valley, California